Kishan, Amar U;
Wang, Xiaoyan;
Sun, Yilun;
Romero, Tahmineh;
Michalski, Jeff M;
Ma, Ting Martin;
Feng, Felix Y;
... Spratt, Daniel E; + view all
(2022)
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium.
European Urology
, 82
(1)
pp. 106-114.
10.1016/j.eururo.2022.04.003.
Preview |
Text (Accepted manuscript)
Sydes_High-dose Radiotherapy or Androgen Deprivation Therapy_AAM.pdf - Accepted Version Download (236kB) | Preview |
Preview |
Text (Tables)
Sydes_High-dose Radiotherapy or Androgen Deprivation Therapy_Tables.pdf - Accepted Version Download (143kB) | Preview |
Preview |
Text (Figures)
Sydes_High-dose Radiotherapy or Androgen Deprivation Therapy_Figures.pdf - Accepted Version Download (537kB) | Preview |
Preview |
Text (Supplement)
Sydes_High-dose Radiotherapy or Androgen Deprivation Therapy_Supplement.pdf - Accepted Version Download (1MB) | Preview |
Abstract
BACKGROUND: The relative benefits of radiotherapy (RT) dose escalation and the addition of short-term or long-term androgen deprivation therapy (STADT or LTADT) in the treatment of prostate cancer are unknown. OBJECTIVE: To perform a network meta-analysis (NMA) of relevant randomized trials to compare the relative benefits of RT dose escalation ± STADT or LTADT. DESIGN, SETTING, AND PARTICIPANTS: An NMA of individual patient data from 13 multicenter randomized trials was carried out for a total of 11 862 patients. Patients received one of the six permutations of low-dose RT (64 to <74 Gy) ± STADT or LTADT, high-dose RT (≥74 Gy), or high-dose RT ± STADT or LTADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Metastasis-free survival (MFS) was the primary endpoint. Frequentist and Bayesian NMAs were performed to rank the various treatment strategies by MFS and biochemical recurrence–free survival (BCRFS). RESULTS AND LIMITATIONS: Median follow-up was 8.8 yr (interquartile range 5.7–11.5). The greatest relative improvement in outcomes was seen for addition of LTADT, irrespective of RT dose, followed by addition of STADT, irrespective of RT dose. RT dose escalation did not improve MFS either in the absence of ADT (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.80–1.18) or with STADT (HR 0.99, 95% CI 0.8–1.23) or LTADT (HR 0.94, 95% CI 0.65–1.37). According to P-score ranking and rankogram analysis, high-dose RT + LTADT was the optimal treatment strategy for both BCRFS and longer-term outcomes. CONCLUSIONS: Conventionally escalated RT up to 79.2 Gy, alone or in the presence of ADT, does not improve MFS, while addition of STADT or LTADT to RT alone, regardless of RT dose, consistently improves MFS. RT dose escalation does provide a high probability of improving BCRFS and, provided it can be delivered without compromising quality of life, may represent the optimal treatment strategy when used in conjunction with ADT.
| Type: | Article |
|---|---|
| Title: | High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.eururo.2022.04.003 |
| Publisher version: | https://doi.org/10.1016/j.eururo.2022.04.003 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10147515 |
Archive Staff Only
 |
View Item |
